Mabworks

What Mabworks does

Mabworks (Beijing Mabworks Biotech Co., Ltd / 北京天广实生物技术股份有限公司) is a Beijing-based clinical-stage biopharmaceutical company founded in 2003 that develops differentiated antibody therapies for autoimmune diseases and hematological malignancies. The company operates five integrated proprietary technology platforms — ADCC-enhanced (CHOK1-AF) antibody, multi-specific (bispecific/trispecific), half-life extended, antibody discovery/optimization, and process development/CMC manufacturing — which together support an in-house pipeline anchored by its commercial product Bejescin® (MIL62, obinutuzumab beta injection), a third-generation anti-CD20 antibody with near-100% fucose knockout. Bejescin was approved by China's NMPA for neuromyelitis optica spectrum disorder (NMOSD) in February 2026 and for primary membranous nephropathy (PMN) in June 2026, making it the world's first approved PMN therapy and China's first domestic NMOSD treatment. Earlier-approved MIL60 (bevacizumab biosimilar, Bei'anting) was co-developed with Betta Pharma and approved in November 2021.

The revenue model combines direct product sales of Bejescin in mainland China through hospital and pharmacy distribution (with Hengrui Pharmaceuticals handling commercial promotion in Greater China and Kaiyin Technology supporting regional market access), out-licensing revenue from a USD 893 million agreement with Climb Bio (NASDAQ: CLYM) for global rights to MIL116 (anti-APRIL) and a CNY 209 million agreement with Everest Medicines (HKEX 1952.HK) for Asia-Pacific commercialization of MIL62, milestone-driven R&D revenue tied to pipeline progress, and CDMO services via the jointly-held Foster Bio subsidiary. Customer segments span autoimmune disease patients (NMOSD, PMN, IgA nephropathy, SLE, gMG, ITP) and oncology patients (B-cell lymphomas including FL/MZL, multiple myeloma), served through scientific conference presentations (ASH, ASN, ERA, ASCO), peer-reviewed publications (The Lancet eClinical Medicine), regulatory milestones, and a network of strategic partners including Hengrui, Climb Bio, Everest, Pfizer Ignite, Kyinno Bio, Betta Pharma, and Jingda Bio.

Name

Mabworks

Legal name

北京天广实生物技术股份有限公司

Website

https://mab-works.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

251–500 employees

Short description

Mabworks is a Beijing-based biopharmaceutical company developing differentiated antibody therapies for autoimmune diseases and oncology, anchored by its approved third-generation anti-CD20 antibody Bejescin (MIL62) and a pipeline of multi-specific and long-acting antibody candidates out-licensed to global partners.

Ownership category

akta.pro rank

Product category

Monoclonal Antibody Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Bispecific & Multispecific Antibodies (HLAAAAAF), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Monoclonal antibody therapeutics
• Biopharmaceutical drug development
• Autoimmune disease therapies
• CD20 antibody therapy
• Oncology biologics pipeline

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Product Sales — Bejescin (MIL62): Mabworks generates revenue from direct sales of its approved drug Bejescin (MIL62, obinutuzumab beta injection) in mainland China following NMPA approval for NMOSD in February 2026 and pMN in June 2026. The product is distributed nationally through pharmaceutical terminals, with the first batch shipment completed in March 2026.
2. Upfront and Milestone Payments — Everest Medicines Asia-Pacific License: Under the licensing agreement with Everest Medicines (HKEX 1952.HK) for Asia-Pacific commercialization rights to MIL62, Mabworks receives up to RMB 209 million (approximately USD 29 million) in upfront and sales milestone payments, plus a share of gross profit from Asia-Pacific sales.
3. Licensing Revenue — Climb Bio MIL116 Global License: Under the licensing agreement with Climb Bio, Inc. (NASDAQ: CLYM), Mabworks receives USD 9 million upfront payment, up to USD 51.75 million in cumulative development milestones, up to USD 832 million in sales milestones, and net sales royalties outside Greater China, totaling up to USD 893 million (approximately USD 893 million) in potential deal value.
4. R&D Services and Milestones: Mabworks generates revenue from milestone payments tied to clinical development progress, NDA approvals, and regulatory designations for its pipeline products including MIL62 (NMOSD and PMN indications) and MIL116 (IgA nephropathy).

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Mabworks discovers, develops, manufactures, and commercializes differentiated monoclonal antibody therapeutics targeting autoimmune diseases and oncology. Its flagship approved product is Bejescin (倍捷欣®, MIL62, obinutuzumab beta injection), a third-generation anti-CD20 antibody approved by NMPA for NMOSD and primary membranous nephropathy (pMN). The pipeline includes long-acting and multi-specific antibodies (MIL116, MBS303, MBS314, MIL60), all built on five proprietary antibody technology platforms covering glycoengineering, multi-specificity, half-life extension, discovery/optimization, and CMC.

Product overview

Mabworks (北京天广实生物技术股份有限公司, Beijing Mabworks Biotech Co. Ltd) is a clinical-stage biopharmaceutical company developing differentiated antibody therapies for autoimmune diseases and oncology. Its core commercial product is Bejescin® (倍捷欣®, MIL62, obinutuzumab beta injection), a third-generation anti-CD20 antibody approved by NMPA for neuromyelitis optica spectrum disorder (NMOSD) and primary membranous nephropathy (pMN) — the world's first approved therapy for pMN. The pipeline includes MIL116 (CLYM116), a long-acting anti-APRIL antibody for IgA nephropathy in Phase I trials licensed to Climb Bio (NASDAQ: CLYM) globally outside Greater China; MBS303/MSC303, a CD20/CD3 bispecific antibody in Phase I/II for B-NHL and immune-mediated glomerulonephritis; and MBS314, a GPRC5D/BCMA/CD3 trispecific antibody in Phase I/II for multiple myeloma, developed with Kyinno Bio. Mabworks's proprietary technology stack comprises four integrated antibody platforms: ADCC-enhanced (glycoengineering), multi-specific, half-life extended, and antibody discovery & optimization platforms, all supporting the pipeline from discovery through GMP manufacturing. The company operates a CDMO subsidiary, Foster Bio (赋成生物), jointly invested with Betta Pharma.

Differentiator

Problem solved

Functional benefit

Brands

• 倍捷欣® (Bejescin®): Brand name for MIL62 (obinutuzumab beta injection), a third-generation anti-CD20 antibody approved for NMOSD and PMN
• 贝安汀® (MIL60)
• 赋成生物 (Foster Bio)

Products and services

• Bejescin (倍捷欣®, MIL62, obinutuzumab beta injection) A third-generation anti-CD20 monoclonal antibody developed on Mabworks' proprietary ADCC-enhanced platform, achieving near-100% fucose knockout through ZFN gene editing. Approved in China for NMOSD and primary membranous nephropathy. Phase III demonstrated 97.5% NMOSD relapse-risk reduction (HR=0.025) and 49.4% complete remission vs 3.9% for cyclosporine at 76 weeks in pMN. Dosage: 1000mg IV at weeks 1, 3, 25, 27, then every 26 weeks.
• MIL116 (CLYM116) A novel long-acting anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody developed on Mabworks' half-life extended antibody platform, using a pH-dependent 'sweeper' mechanism combined with Fc region half-life extension. In Phase I trials for IgA nephropathy (IgAN); Mabworks retains Greater China rights and is conducting a parallel China Phase 1/2 with Phase 2 IgAN dosing expected in Q3 2026.
• MBS303 (MSC303) A CD20/CD3 bispecific T-cell engager (TCE) developed on Mabworks' multi-specific antibody platform using a 2:1 asymmetric antibody structure. In Phase I/II trials for B-cell non-Hodgkin lymphoma (B-NHL) and Phase I for immune-mediated glomerulonephritis.
• MBS314 A first-in-class GPRC5D/BCMA/CD3 trispecific T-cell engager co-developed with Kyinno Bio. In Phase I/II trials for relapsed/refractory multiple myeloma. Phase I data presented at ASH 2024 showed 60% ORR at doses ≥3mg, with 75% VGPR rate in BCMA-pretreated patients. IND approved by both China NMPA and US FDA (subcutaneous formulation).
• MIL60 (Bei'anting 贝安汀, bevacizumab biosimilar) A bevacizumab biosimilar co-developed with Betta Pharma. NMPA-approved for metastatic colorectal cancer and NSCLC. Manufactured through Mabworks' CMC platform and Foster Bio CDMO.
• Foster Bio (赋成生物) CDMO Services Contract Development and Manufacturing Organization (CDMO) service platform providing GMP-compliant process development and manufacturing services for biologic macromolecule drugs, co-invested with Betta Pharma and operated as an independent Mabworks subsidiary.

Quantifiable outcome

• MIL62 monotherapy reduced NMOSD relapse risk by 97.5% vs placebo (HR=0.025, P<0.0001), with 0% new relapse events during trial period and ARR of only 0.028/person-year
• +6 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Nine partnerships are on record, tiered core, major and minor.

• Everest Medicines (云顶新耀, HKEX 1952.HK)coreChannel Partner/ Reseller/ Distributor · 4 June 2026Mabworks granted Everest Medicines (HKEX 1952.HK) exclusive rights for clinical development and commercialization of MIL62 (Bejescin) in Asia-Pacific regions including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong, Macau, and Taiwan. Financial terms include up to CNY 209 million in upfront and sales milestone payments plus gross margin sharing from regional sales. Everest Medicines has established commercialization capabilities in nephrology and autoimmune diseases.
• Climb Bio, Inc. (NASDAQ: CLYM)coreOEM/ Whitelabel/ Licensing Partner · 10 January 2025Mabworks entered into a licensing agreement with Climb Bio, Inc. (NASDAQ: CLYM) granting exclusive rights outside Greater China for development, manufacturing, and commercialization of MIL116 (CLYM116), an anti-APRIL antibody for IgA nephropathy. Financial terms include USD 9 million upfront, up to USD 51.75 million in development milestones, up to USD 832 million in sales milestones, and net sales royalties. Total deal value up to USD 893 million. Climb Bio presented Phase 1 safety data for CLYM116 at ERA 2026 in June 2026.
• Kyinno Bio (康源博创生物科技)coreStrategic or Co-development Partner · 10 January 2025Mabworks co-develops MBS314 (GPRC5D/BCMA/CD3 trispecific antibody) with Kyinno Bio for multiple myeloma treatment. Kyinno contributed its bispecific/trispecific antibody discovery platform. The partnership includes co-funding of global IND applications, including FDA approval for subcutaneous formulation Phase I trial in January 2025. Joint development costs and IP are shared, with Mabworks holding certain commercial rights.
• Pfizer Inc. (via Ignite Program)majorStrategic or Co-development Partner · 6 November 2024Mabworks and co-development partner Kyinno Bio signed a cooperation memorandum with Pfizer at the 7th China International Import Expo (CIIE), establishing a collaboration under Pfizer's Ignite program for global clinical development of MBS314, a CD3/BCMA/GPRC5D trispecific antibody for multiple myeloma. This marks Pfizer Ignite's first collaboration with a mainland Chinese biotech company.
• Jingda Bio (景达生物)minorStrategic or Co-development Partner · 22 October 2021Mabworks and Jingda Bio entered a strategic collaboration to develop combined therapies using Jingda's universal NK cell therapy with Mabworks' ADCC-enhanced antibodies (MIL62 and MIL93). The collaboration targets joint preclinical and clinical development for hematological and solid tumor indications, leveraging the synergy between NK cell therapies and ADCC-enhanced antibody drugs.
• Hengrui Pharmaceuticals (恒瑞医药, SSE: 600276)majorChannel Partner/ Reseller/ Distributor · 5 September 2021Mabworks granted Hengrui Pharmaceuticals exclusive commercialization rights for MIL62 in Greater China, and agreed to conduct joint clinical studies combining MIL62 with Hengrui products. Hengrui also expressed preliminary equity investment intention of approximately USD 30 million as a cornerstone investor.
• Kaiyin Technology (凯因科技, SSE: 688687)minorChannel Partner/ Reseller/ DistributorMabworks established product commercialization partnership with Kaiyin Technology (688687.SH) for its products in designated regions in China, leveraging Kaiyin's established market promotion and sales network infrastructure.
• Betta Pharma (贝达药业, SZSE: 300558)majorTechnology or IntegrationMabworks co-invests in Foster Bio (赋成生物), an independently operated CDMO service platform, with Betta Pharma (300558.SZ). Foster Bio provides process development and manufacturing services. Mabworks MIL60 (bevacizumab biosimilar, marketed as Bei'anting) was jointly developed with Betta Pharma and approved in November 2021 for metastatic colorectal cancer and NSCLC.
• Beijing Mabworks Biotech / MabworkscoreTechnology or IntegrationWithin the Climb Bio partnership, Mabworks' entity Beijing Mabworks Biotech conducts a parallel Phase 1 study of CLYM116 in China and expects to initiate Phase 2 dosing in IgAN patients in Q3 2026. Mabworks retains Greater China rights and executes independent China clinical development.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Innovent Biologics: Innovent is a leading Chinese innovative biotech developing monoclonal and bispecific antibodies in oncology and autoimmune disease, with multiple approved and commercialized biologics (e.g., sintilimab, mazdutide). Directly comparable as a Chinese antibody specialist with global out-licensing deals and NMPA-approved biologics in similar indications.
• BeiGene: BeiGene is a global Chinese biotech with approved BTK and PD-1 antibodies and significant commercial operations in China and the US. Comparable as a domestically headquartered innovative antibody company with global commercialization capability and broad pipeline in oncology and immunology.
• Junshi Biosciences: Junshi is a Shanghai-based Chinese biotech pioneering anti-PD-1 antibodies (toripalimab) and developing bispecifics and antibody-drug conjugates. Directly comparable as a Chinese antibody innovator with NMPA-approved products, US/global out-licensing deals, and a similar pipeline focus on autoimmune and oncology biologics.
• Akeso, Inc. Akeso is a Guangdong-based Chinese biotech known for bispecific and multispecific antibody innovation (e.g., ivonescimab, cadonilimab), with multiple NMPA approvals in oncology. Highly comparable to Mabworks in bispecific/trispecific platform strategy and Chinese-first commercialization model.
• RemeGen Co., Ltd. RemeGen is a Shandong-based Chinese biotech developing antibody-drug conjugates and bispecifics with approved products (disitamab vedotin, telitacicept) in oncology and autoimmune disease. Comparable as a Chinese antibody specialist with NMPA approvals in autoimmune and oncology indications.

Broad incumbents

• Roche: Roche markets obinutuzumab (Gazyva), the original third-generation CD20 antibody that Bejescin (obinutuzumab beta) is biosimilar-to/me-too of. As the originator of anti-CD20 antibodies including rituximab, Roche is the dominant incumbent that Mabworks competes against in CD20-targeting indications and autoimmune disease.
• Hansoh Pharmaceutical Group: Hansoh is a leading Chinese innovative pharmaceutical company with a significant biologics and antibody pipeline. Comparable as a larger established Chinese pharma with NMPA-approved innovative biologics, although Hansoh has a broader small-molecule portfolio.

Others

• Hengrui Pharmaceuticals: Hengrui is a top Chinese innovative pharma company with broad biologics and small-molecule capabilities. Listed as a key strategic partner (USD 30M equity investor and commercial promotion partner for MIL62 in Greater China), making Hengrui both a commercialization ally and an ecosystem comparable in the broader Chinese innovative biopharma landscape.
• WuXi Biologics: WuXi Biologics is the world's largest biologics CDMO, directly comparable to Mabworks' Foster Bio subsidiary in providing contract development and manufacturing services for biologics. WuXi represents both a competitor in CDMO services and a benchmark for biologics manufacturing capability.

Emerging players

• ChemoCentryx / Amgen (CCX168 / Tavneos): Amgen (via ChemoCentryx acquisition) markets tavneos for ANCA-associated vasculitis and is developing complement inhibitors for IgA nephropathy and other autoimmune kidney diseases. Relevant as an emerging player in autoimmune renal disease, a therapeutic area where Mabworks' Bejescin (PMN) and MIL116 (IgAN) compete.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mabworks-biotech-co.-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mabworks